The IGA has co-authored an article 'The Definition of Neuronopathic Gaucher disease' published in the Journal of Inherited Metabolic Disease.
CEO, Tanya Collin-Histed writes "Proud to have been a part of this publication. These are exciting times for our neuronopathic community with so much interest in research and medicines development. This new definition will help patients and clinicians with diagnosis and ultimately ensure that patients with nGD are able to access new medicines and the right clinical care. We are also excited that the new IGA Global patient led registry will use this definition to ensure that only Gaucher patients with type 2 and 3 are included in the registry."
You can read the article here